Royal Bank of Canada Fires CFO After Investigation
By Mary de Wet
Royal Bank of Canada said it terminated Finance Chief Nadine Ahn's employment after an investigation found Ahn had an undisclosed relationship with an employee that led to preferential treatment for that employee.
The bank appointed Katherine Gibson as its interim chief financial officer.
Ahn couldn't immediately be reached for comment.
Ahn was named finance chief in November 2021 after more than 20 years in finance roles with the bank.
RBC said it launched an internal review after being made aware of allegations involving Ahn.
The investigation found evidence that Ahn was in an undisclosed close personal relationship with another employee that led to promotion and compensation increases for that employee, the bank said.
The bank said it has terminated the employment of that worker.
The investigation found no evidence of conduct by the former finance chief or the other employee with respect to the bank's previously issued financial statements, RBC's strategy or its financial or business performance, RBC said.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
April 05, 2024 20:46 ET (00:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks